ArGEN-X focuses on the discovery and development of human antibodies using its proprietary SIMPLE Antibody (TM) platform. The platform generates a limitless source of extremely high quality human antibodies that modulate the function of disease targets, including complex receptors and highly conserved targets, that are not possible to generate with other antibody technologies. The Lead antibodies generated are further differentiated through enhancement of their cell killing properties (Potelligent® technology) and circulation time in the body (NHance™ technology). arGEN-X’s portfolio consists of novel programs addressing oncology, autoimmune and inflammation indications.
Total raised: $148.45M
Investors 2
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Omnes Capi... | omnescapit... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 03.06.2016 | - | $33M | - |
| 04.11.2013 | Series B | $44M | - |
| 01.12.2011 | Series B | $37.05M | - |
| 01.12.2011 | Grant | $1.7M | - |
Mentions in press and media 16
| Date | Title | Description |
| 18.05.2017 | Term Sheet — Thursday, May 18 | DOING THEIR OWN THING It’s fairly normal for successful venture capital pros to spend their careers building up a track record at a larger firm, and then “spin off” with their own firms. Lately, as limited partner interest in venture contin... |
| 09.05.2017 | Term Sheet — Tuesday, May 9 | PROFITABILITY OVER PASSION Land of Opportunity: Yesterday’s Term Sheet included a link to this story about SoftBank’s ambitions in India that deserves a little more attention. Like so many articles about tech in India, this one draws compar... |
| 24.04.2017 | NASDAQ bound: Argenx eyes a $75 million IPO | Argenx has raised significant cash to date through equity financing rounds and previous share offerings, following its listing on the Euronext Brussels exchange in mid-2014. It also stands to earn up to €2 billion through partnerships with ... |
| 24.04.2017 | Term Sheet — Monday, April 24 | OPEN MIC It’s feedback time. Paid Content Securing the enterprise without boundaries From ExtraHop Joe writes: Expecting evidence of transparency before investing, either crowdfunding, angel or venture, would improve outcomes for investors.... |
| 03.06.2016 | Fresh from its AbbVie cancer pact, argenx raises $33M with U.S. investors | After Belgium biotech argenx signed a preclinical immuno-oncology deal with U.S. giant AbbVie ($ABBV) for $685 million back in April, it has now also raised $33 million in the country as it looks to expand its footprint in the U.S. The comp... |
| 07.11.2013 | arGEN-X Extends Series B Funds to $44M | BREDA, THE NETHERLANDS, arGEN-X, a biotech company developing therapeutic antibodies, has extended its Series B financing round with an additional $6.8 million (5 million euro) in funds. >> Click here for more funding data on arGEN... |
| 06.11.2013 | arGEN-X Raises Additional €5M in Series B Financing Round | arGEN-X, a Breda, The Netherlands- and Zwijnaarde, Belgium-based clinical state human therapeutic antibody company, raised an additional €5m as an extension of its Series B financing round from new investor PMV. The Series B round, which ha... |
| 16.05.2013 | With a band of biotech collaborators, RuiYi sets sail developing new biologic drugs for China | “There’s already an approved antibody that targets the receptor; ours targets the cytokine, so you can actually use a lot less,” Grayson said. “It’s a known biologic mechanism, and there’s a lot of data showing that it’s safe and it has the... |
| 20.12.2011 | arGEN-X Receives €1.3M Grant | arGEN-X, a Rotterdam, The Nederlands-based biopharmaceutical company focused on the discovery and development of human monoclonal antibodies, has received a €1.3m grant from the Institute for the Promotion of Innovation by Science and Techn... |
| 01.12.2011 | arGEN-X Closes €27.5M Series B Funding Round | arGEN-X, a Rotterdam, The Nederlands-based biopharmaceutical company focused on the discovery and development of human monoclonal antibodies, closed a €27.5m (US$37m) Series B funding. The round was co-led by OrbiMed Advisors and Seventure ... |
Show more